<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04568161</url>
  </required_header>
  <id_info>
    <org_study_id>Breast Cancer Chemotherapy</org_study_id>
    <nct_id>NCT04568161</nct_id>
  </id_info>
  <brief_title>Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses</brief_title>
  <official_title>Chronic Effect of Doxorubicin and Cyclophosphamide on Neurovascular Control and Blood Pressure in Women in Adjuvant Treatment for Breast Neoplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidade Federal Fluminense</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Israelita Albert Einstein</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims to investigate the chronic effect of treatment with doxorubicin and&#xD;
      cyclophosphamide on neurovascular control and blood pressure in women undergoing adjuvant&#xD;
      treatment for breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The development of new drugs and different adjuvant therapeutic regimens, based on the&#xD;
      combination of anthracycline (A) and cyclophosphamide (C), have contributed greatly to&#xD;
      improve survival rate in breast cancer patients. Despite the clinical benefits of this&#xD;
      therapy, AC treatment can cause cardiovascular acute and chronic changes. In a recent&#xD;
      investigation, we observed that an acute AC chemotherapy session increases sympathetic&#xD;
      nervous activity and blood pressure in patients with breast cancer.&#xD;
&#xD;
      The present study aims to investigate the chronic effects of AC regimen on sympathetic&#xD;
      nervous activity, peripheral vasoconstriction, endothelial microparticles and blood pressure,&#xD;
      in women with breast cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2020</start_date>
  <completion_date type="Anticipated">November 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 3, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle sympathetic nerve activity</measure>
    <time_frame>15-20 days after the end of AC regimen</time_frame>
    <description>Change in muscular sympathetic nerve activity measured by microneurography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle blood flow</measure>
    <time_frame>15-20 days after the end of AC regimen</time_frame>
    <description>Change in muscle blood flow measured by venous oclusion plethysmography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>15-20 days after the and of AC regimen</time_frame>
    <description>Change in blood pressure measured by finometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical capacity</measure>
    <time_frame>15-20 days after the end of AC regimen</time_frame>
    <description>Change in physical capacity measured by cardiopulmonary exercise test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Function Impairment</measure>
    <time_frame>15-20 days after the end of AC regimen</time_frame>
    <description>Change in cardiac function measured by echocardiography</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Cardiotoxicity</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Neurovascular Disorder</condition>
  <condition>Endothelial Disfunction</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>pre and post chemotherapy assessments</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will be assessed before and after chemotherapy treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Physical Characteristics</intervention_name>
    <description>Body weight, height and waist circumference</description>
    <arm_group_label>pre and post chemotherapy assessments</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Muscular Sympathetic Nervous Activity</intervention_name>
    <description>Microneurography technique.</description>
    <arm_group_label>pre and post chemotherapy assessments</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac Function</intervention_name>
    <description>Echocardiography.</description>
    <arm_group_label>pre and post chemotherapy assessments</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Heart rate</intervention_name>
    <description>Electrocardiography</description>
    <arm_group_label>pre and post chemotherapy assessments</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood pressure</intervention_name>
    <description>Non-invasive photoplethysmography.</description>
    <arm_group_label>pre and post chemotherapy assessments</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood Assessments</intervention_name>
    <description>Serum and Plasma will be extracted by centrifugation. Endothelial microparticles by flow cytometry Interleukin-6 and tumor necrosis factor Î± by ELISA, High-sensitive reactive serum C-reactive protein by immunoturbidimetric assay, NT- ProBNP According to Central Laboratory, Hospital das Clinicas, HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo. Endothelin-1 by immunoenzymatic method Nitric oxide by gas chemiluminescence Lipoperoxidation by fluorimetry Carbonyl by spectrophotometer, and Superoxide Dismutase (SOD) by colorimetry.</description>
    <arm_group_label>pre and post chemotherapy assessments</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Muscle blood flow</intervention_name>
    <description>Venous occlusion plethysmography</description>
    <arm_group_label>pre and post chemotherapy assessments</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Endothelium-dependent vascular function</intervention_name>
    <description>Brachial ultrasound</description>
    <arm_group_label>pre and post chemotherapy assessments</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Vascular intima-media thickness</intervention_name>
    <description>Carotid ultrasound</description>
    <arm_group_label>pre and post chemotherapy assessments</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Physical Capacity</intervention_name>
    <description>Cardiopulmonary exercise test</description>
    <arm_group_label>pre and post chemotherapy assessments</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anthracycline &amp; Cyclophosphamide treatment scheme</intervention_name>
    <description>Four session of intravenous (in bolus) infusion of doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 with an interval of 21 days between sessions.</description>
    <arm_group_label>pre and post chemotherapy assessments</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of stage II-III breast cancer&#xD;
&#xD;
          -  starting adjuvant chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  metastatic disease,&#xD;
&#xD;
          -  hypercholesterolemia, diabetes,&#xD;
&#xD;
          -  hypertension,&#xD;
&#xD;
          -  severe lymphedema,&#xD;
&#xD;
          -  organic disorders (renal failure, heart failure and chronic liver disease),&#xD;
&#xD;
          -  obesity (BMI&gt; 30) and,&#xD;
&#xD;
          -  who are under pharmacological treatment with statins, angiotensin-converting enzyme&#xD;
             inhibitors, losartan potassium, beta blockers or antioxidants&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos E Negrao, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto do Coracao, HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raphaela VR Groehs, PhD</last_name>
    <phone>551126615699</phone>
    <email>rapha_vilar@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ursula Urias, PhD</last_name>
    <phone>551126615699</phone>
    <email>uurias@usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raphaela VR Groehs, PhD</last_name>
      <phone>551126615699</phone>
      <email>rapha_vilar@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ursula Urias, PhD</last_name>
      <phone>551126615699</phone>
      <email>uurias@usp.br</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos Eduardo Negrao, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.</citation>
    <PMID>30620402</PMID>
  </reference>
  <reference>
    <citation>Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000 Apr;22(4):263-302. Review.</citation>
    <PMID>10789823</PMID>
  </reference>
  <reference>
    <citation>Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol. 2008 Nov;130(5):688-95. doi: 10.1309/AJCPB66LRIIVMQDR. Review.</citation>
    <PMID>18854260</PMID>
  </reference>
  <reference>
    <citation>Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002 May;13(5):699-709.</citation>
    <PMID>12075737</PMID>
  </reference>
  <reference>
    <citation>Sales ARK, NegrÃ£o MV, Testa L, Ferreira-Santos L, Groehs RVR, Carvalho B, Toschi-Dias E, Rocha NG, Laurindo FRM, Debbas V, Rondon MUPB, Mano MS, Hajjar LA, Hoff PMG, Filho RK, NegrÃ£o CE. Chemotherapy acutely impairs neurovascular and hemodynamic responses in women with breast cancer. Am J Physiol Heart Circ Physiol. 2019 Jul 1;317(7):H1-H12. doi: 10.1152/ajpheart.00756.2018. Epub 2019 Apr 19.</citation>
    <PMID>31002284</PMID>
  </reference>
  <reference>
    <citation>Soultati A, Mountzios G, Avgerinou C, Papaxoinis G, Pectasides D, Dimopoulos MA, Papadimitriou C. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev. 2012 Aug;38(5):473-83. doi: 10.1016/j.ctrv.2011.09.002. Epub 2011 Oct 6. Review.</citation>
    <PMID>21982720</PMID>
  </reference>
  <reference>
    <citation>Laterza MC, de Matos LD, Trombetta IC, Braga AM, Roveda F, Alves MJ, Krieger EM, NegrÃ£o CE, Rondon MU. Exercise training restores baroreflex sensitivity in never-treated hypertensive patients. Hypertension. 2007 Jun;49(6):1298-306. Epub 2007 Apr 16.</citation>
    <PMID>17438307</PMID>
  </reference>
  <reference>
    <citation>Barretto AC, Santos AC, Munhoz R, Rondon MU, Franco FG, Trombetta IC, Roveda F, de Matos LN, Braga AM, Middlekauff HR, NegrÃ£o CE. Increased muscle sympathetic nerve activity predicts mortality in heart failure patients. Int J Cardiol. 2009 Jul 10;135(3):302-7. doi: 10.1016/j.ijcard.2008.03.056. Epub 2008 Jun 26.</citation>
    <PMID>18582965</PMID>
  </reference>
  <reference>
    <citation>Jenkins NT, Padilla J, Boyle LJ, Credeur DP, Laughlin MH, Fadel PJ. Disturbed blood flow acutely induces activation and apoptosis of the human vascular endothelium. Hypertension. 2013 Mar;61(3):615-21. doi: 10.1161/HYPERTENSIONAHA.111.00561. Epub 2013 Jan 14.</citation>
    <PMID>23319545</PMID>
  </reference>
  <reference>
    <citation>NegrÃ£o CE, Rondon MU, Tinucci T, Alves MJ, Roveda F, Braga AM, Reis SF, Nastari L, Barretto AC, Krieger EM, Middlekauff HR. Abnormal neurovascular control during exercise is linked to heart failure severity. Am J Physiol Heart Circ Physiol. 2001 Mar;280(3):H1286-92.</citation>
    <PMID>11179075</PMID>
  </reference>
  <reference>
    <citation>Granger DL, Anstey NM, Miller WC, Weinberg JB. Measuring nitric oxide production in human clinical studies. Methods Enzymol. 1999;301:49-61. Review.</citation>
    <PMID>9919553</PMID>
  </reference>
  <reference>
    <citation>Kovachich GB, Mishra OP. Lipid peroxidation in rat brain cortical slices as measured by the thiobarbituric acid test. J Neurochem. 1980 Dec;35(6):1449-52.</citation>
    <PMID>7441260</PMID>
  </reference>
  <reference>
    <citation>Thijssen DHJ, Bruno RM, van Mil ACCM, Holder SM, Faita F, Greyling A, Zock PL, Taddei S, Deanfield JE, Luscher T, Green DJ, Ghiadoni L. Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans. Eur Heart J. 2019 Aug 7;40(30):2534-2547. doi: 10.1093/eurheartj/ehz350.</citation>
    <PMID>31211361</PMID>
  </reference>
  <reference>
    <citation>Abdel-Sayed S, Nussberger J, Aubert JF, Gohlke P, Brunner HR, Brakch N. Measurement of plasma endothelin-1 in experimental hypertension and in healthy subjects. Am J Hypertens. 2003 Jul;16(7):515-21.</citation>
    <PMID>12850383</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chemotherapy</keyword>
  <keyword>Endothelial Disfunction</keyword>
  <keyword>Muscle Sympathetic Nerve Activity</keyword>
  <keyword>Blood Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

